

Iacopo Baussano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5899702/publications.pdf>

Version: 2024-02-01

62
papers

2,679
citations

279487

23
h-index

197535

49
g-index

70
all docs

70
docs citations

70
times ranked

3557
citing authors

#	ARTICLE	IF	CITATIONS
1	Age-specific burden of cervical cancer associated with HIV: A global analysis with a focus on sub-Saharan Africa. <i>International Journal of Cancer</i> , 2022, 150, 761-772.	2.3	19
2	Predicting Cohort-Specific Cervical Cancer Incidence From Population-Based Surveys of Human Papilloma Virus Prevalence: A Worldwide Study. <i>American Journal of Epidemiology</i> , 2022, 191, 402-412.	1.6	7
3	Estimates of the global burden of cervical cancer associated with HIV. <i>The Lancet Global Health</i> , 2021, 9, e161-e169.	2.9	319
4	Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. <i>Clinical Infectious Diseases</i> , 2021, 72, e890-e892.	2.9	5
5	Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation. <i>JCO Global Oncology</i> , 2021, 7, 416-424.	0.8	34
6	The role and utility of population-based cancer registries in cervical cancer surveillance and control. <i>Preventive Medicine</i> , 2021, 144, 106237.	1.6	17
7	Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. <i>Lancet Public Health, The</i> , 2021, 6, e510-e521.	4.7	39
8	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 1598-1610.	4.6	34
9	Prospects for accelerated elimination of cervical cancer. <i>Preventive Medicine</i> , 2021, 153, 106827.	1.6	9
10	Human papillomavirus genotypes in cervical and other HPV-related anogenital cancer in Rwanda, according to HIV status. <i>International Journal of Cancer</i> , 2020, 146, 1514-1522.	2.3	23
11	Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women. <i>International Journal of Cancer</i> , 2020, 147, 440-447.	2.3	8
12	Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018. <i>Annals of Internal Medicine</i> , 2020, 173, 888-894.	2.0	14
13	The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. <i>Lancet Public Health, The</i> , 2020, 5, e592-e603.	4.7	16
14	Prevention is life- and cost-saving. <i>Preventive Medicine</i> , 2020, 138, 106150.	1.6	1
15	Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied. <i>Journal of Infectious Diseases</i> , 2020, 222, 948-956.	1.9	29
16	Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. <i>Vaccine</i> , 2020, 38, 4001-4005.	1.7	27
17	Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. <i>Emerging Infectious Diseases</i> , 2020, 27, 1-9.	2.0	21
18	Eradication of human papillomavirus and elimination of HPV-related diseases – scientific basis for global public health policies. <i>Expert Review of Vaccines</i> , 2019, 18, 153-160.	2.0	41

#	ARTICLE	IF	CITATIONS
19	Modelling cervical cancer elimination. <i>Lancet Public Health, The</i> , 2019, 4, e2-e3.	4.7	11
20	Impacts of human papillomavirus vaccination for different populations: A modeling study. <i>International Journal of Cancer</i> , 2018, 143, 1086-1092.	2.3	18
21	Options for design of real-world impact studies of single-dose vaccine schedules. <i>Vaccine</i> , 2018, 36, 4816-4822.	1.7	11
22	Impact of gender-neutral or girls-only vaccination against human papillomavirus: Results of a community-randomized clinical trial (I). <i>International Journal of Cancer</i> , 2018, 142, 949-958.	2.3	42
23	Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). <i>International Journal of Cancer</i> , 2018, 143, 2299-2310.	2.3	46
24	Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda. <i>BMC Women's Health</i> , 2018, 18, 59.	0.8	18
25	Effect of age-difference between heterosexual partners on risk of cervical cancer and human papillomavirus infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 98-104.	4.5	6
26	Causal system modelling of cervical cancer screening. <i>Lancet Public Health, The</i> , 2017, 2, e61-e62.	4.7	1
27	Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study. <i>Journal of Infectious Diseases</i> , 2017, 216, 336-344.	1.9	20
28	Cervical cancer screening in rural Bhutan with the <i>care</i> HPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan). <i>BMJ Open</i> , 2017, 7, e016309.	0.8	15
29	Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan. <i>Virology Journal</i> , 2017, 14, 74.	1.4	22
30	Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference. <i>Preventive Medicine</i> , 2017, 98, 21-30.	1.6	49
31	Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. <i>Oncotarget</i> , 2017, 8, 72438-72446.	0.8	8
32	Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior. <i>Emerging Infectious Diseases</i> , 2016, 22, 18-23.	2.0	20
33	Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. <i>International Journal of Cancer</i> , 2016, 139, 518-526.	2.3	38
34	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. <i>Lancet Public Health, The</i> , 2016, 1, e8-e17.	4.7	210
35	Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. <i>BMC Infectious Diseases</i> , 2016, 16, 225.	1.3	40
36	Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. <i>Journal of Infectious Diseases</i> , 2016, 213, 199-205.	1.9	56

#	ARTICLE	IF	CITATIONS
37	HPV-FASTER: broadening the scope for prevention of HPV-related cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 119-132.	12.5	154
38	Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial. <i>Vaccine</i> , 2015, 33, 1284-1290.	1.7	40
39	Introduction of a National HPV vaccination program into Bhutan. <i>Vaccine</i> , 2015, 33, 3726-3730.	1.7	51
40	Naturally Acquired Immunity Against Human Papillomavirus (HPV): Why It Matters in the HPV Vaccine Era. <i>Journal of Infectious Diseases</i> , 2014, 210, 507-509.	1.9	16
41	Cervical cancer screening program in Thimphu, Bhutan: population coverage and characteristics associated with screening attendance. <i>BMC Women's Health</i> , 2014, 14, 147.	0.8	8
42	Upscaling human papillomavirus vaccination in high-income countries: impact assessment based on transmission model. <i>Infectious Agents and Cancer</i> , 2014, 9, 4.	1.2	14
43	Yield of tuberculosis contact investigation in a low-incidence country. <i>Journal of Infection</i> , 2014, 68, 448-454.	1.7	10
44	Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. <i>BMC Infectious Diseases</i> , 2014, 14, 408.	1.3	22
45	Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. <i>International Journal of Cancer</i> , 2013, 133, 1876-1881.	2.3	14
46	Comparison of HPV DNA testing in cervical exfoliated cells and tissue biopsies among HIV-positive women in Kenya. <i>International Journal of Cancer</i> , 2013, 133, 1441-1446.	2.3	17
47	High Rates of <i>Mycobacterium tuberculosis</i> among Socially Marginalized Immigrants in Low-Incidence Area, 1991-2010, Italy. <i>Emerging Infectious Diseases</i> , 2013, 19, 1437-1445.	2.0	17
48	Vaccinating Women Previously Exposed to Human Papillomavirus: A Cost-Effectiveness Analysis of the Bivalent Vaccine. <i>PLoS ONE</i> , 2013, 8, e75552.	1.1	19
49	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171.	1.1	21
50	Outcomes of a tuberculosis contact investigation programme in Italy. <i>European Respiratory Journal</i> , 2012, 40, 1291-1293.	3.1	0
51	Evaluation of Immigrant Tuberculosis Screening in Industrialized Countries. <i>Emerging Infectious Diseases</i> , 2012, 18, 1422-1429.	2.0	90
52	Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. <i>Vaccine</i> , 2011, 29, 1270-1277.	1.7	24
53	Tuberculosis among Health Care Workers. <i>Emerging Infectious Diseases</i> , 2011, 17, 488-494.	2.0	263
54	Tuberculosis Incidence in Prisons: A Systematic Review. <i>PLoS Medicine</i> , 2010, 7, e1000381.	3.9	258

#	ARTICLE	IF	CITATIONS
55	HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. <i>Epidemics</i> , 2010, 2, 21-28.	1.5	27
56	Does language matter? A case study of epidemiological and public health journals, databases and professional education in French, German and Italian. <i>Emerging Themes in Epidemiology</i> , 2008, 5, 16.	1.2	13
57	Continuous Positive Airway Pressure for Treatment of Respiratory Complications After Abdominal Surgery. <i>Annals of Surgery</i> , 2008, 247, 617-626.	2.1	154
58	Risk of tuberculin conversion among healthcare workers and the adoption of preventive measures. <i>Occupational and Environmental Medicine</i> , 2007, 64, 161-166.	1.3	34
59	Neonatal Screening for Cystic Fibrosis Does Not Affect Time to First Infection with <i>Pseudomonas aeruginosa</i> . <i>Obstetrical and Gynecological Survey</i> , 2007, 62, 20-21.	0.2	0
60	Expected number of childhood cancers in Italy from 2001 to 2015. <i>Haematologica</i> , 2007, 92, 1258-1261.	1.7	6
61	Feasibility of recruiting a birth cohort through the Internet: the experience of the NINFEA cohort. <i>European Journal of Epidemiology</i> , 2007, 22, 831-837.	2.5	83
62	Neonatal Screening for Cystic Fibrosis Does Not Affect Time to First Infection With <i>Pseudomonas aeruginosa</i> . <i>Pediatrics</i> , 2006, 118, 888-895.	1.0	22